Genmab reports three positive Phase 3 readouts, eyeing 2027 launches
Genmab reported three positive Phase 3 readouts across oncology assets, per TradingView, with potential launches beginning in 2027.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, Genmab has announced three positive topline readouts from Phase 3 studies. Epcoritamab improved progression-free survival in frontline diffuse large B-cell lymphoma. Rina-S improved progression-free and overall survival in platinum-resistant ovarian cancer. Petosemtamab improved overall survival and objective response rate in first-line head and neck cancer.
A second report of the same news adds that colorectal data for petosemtamab support its expansion. The results point to potential launches beginning in 2027 and broader growth of the company's oncology franchise.
why it matters
For Genmab investors, the readouts matter as evidence that the pipeline is advancing. Positive Phase 3 data reduce uncertainty about future sales and make regulatory filings more likely, though the news is unlikely to move broader markets.
market impact
Genmab: positive Phase 3 data raise expectations for future drug sales
tags
instruments
sources
- GMAB: Three positive Phase 3 readouts open potential 2027 launches across three oncology assets — TradingView, 28 October 2026 at 17:06 UTC
- GMAB: Three positive phase III readouts set up potential launches beginning in 2027 — TradingView, 28 October 2026 at 18:10 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗